EFPIA - European Federation of Pharmaceutical Industries and Associations

#Imagine if Europe found the treatment to slow Alzheimer’s progression, produced the first vaccine for brain cancer or medicines that could transform the lives of patients with chronic disease. Now we've imagined. Let's take action: https://shorturl.at/cCGVZ #WeWontRest

Healthy populations are essential for Europe to achieve its vision of a secure, competitive, and prosperous continent. Yet, European health systems are navigating a perfect storm. Amid these challenges, we must not lose sight of the extraordinary era we are living in—one of rapidly advancing science and innovation, transforming health and unlocking new possibilities for Europe’s present and future generations. Keeping the health sector high on the political agenda is essential for the well-being of Europeans, a resilient workforce, the growth of the EU economy, and the security of Europe. This is why, during this EU mandate, we need a robust and integrated strategy for health policy. What needs to be done in practice? Join the #EUHealthSummit on 28 January to help shape a roadmap for a healthier Europe: https://lnkd.in/d_cJau7S #Vision4Health

Developing new #antimicrobials is essential to tackle #AMR, as existing treatments lose effectiveness over time. However, the antimicrobial R&D #pipeline remains fragile and severely underfunded due to scientific and economic challenges. Unlike other types of drugs, antimicrobials should be used sparingly to limit resistance, which leads to low revenue and frequent bankruptcies in the sector. As discussions on the #EUPharmaLegislation progress, policymakers have a unique opportunity to establish a predictable mechanism for urgent and much-needed sustainable antimicrobial R&D. By seizing this moment, Europe can play a leading role in the global response to AMR, delivering vital treatments for patients and securing substantial economic benefits. Read more: https://lnkd.in/d8j2gXUf #AMRWeek2024 #WeWontRest

Over the last 10 years, the EU’s share of #clinical #trials has halved. In the meantime, China has doubled its number of trials. How can we close the gap and ensure people living in Europe don’t miss out on the opportunity to access the latest medicines? Read more: https://lnkd.in/diW-3ZjK   #WeWontRest #RebootLifeSciences

EFPIA - European Federation of Pharmaceutical Industries and Associations has published new research providing an in-depth analysis on the economic and societal footprint of the pharmaceutical industry in Europe. The data underscores how the pharmaceutical sector is a key pillar of the EU economy. Did you know? • It is x3 as productive as the European economy • It contributes a total of €311 billion to the EU economy • It supports 2.3 million jobs in the EU Europe has a strong track record of recognising and responding to the need for investment in healthcare. But in many countries the principle is now threatened by short-term financial thinking, ageing populations and a projected increase in the burden of chronic illness. At the same time, there is increased competition from China and the US, and Europe risks falling behind. We must reboot our industry’s potential and prioritise its growth potential. Continued investment is crucial to improve societal outcomes, build resilient systems and enable patient access to innovative new therapies, whilst boosting economic productivity. At Johnson and Johnson, we innovate with purpose to lead where medicine is going and push boundaries and deliver groundbreaking treatments for those who need it most. We see health as an investment, not a cost. For more information, the full report can be accessed here: https://brnw.ch/21wONVd #ValueOfHealth #EFPIA #EconomicGrowth

The time is now for EU policymakers to show leadership in the fight against antimicrobial resistance. The revision of the EU pharma legislation is a once-in-a-generation opportunity to establish a robust pull incentive to reinvigorate the antimicrobial pipeline. Here I make the case for transferable exclusivity vouchers as the most promising solution: https://lnkd.in/e2YfvWN3 Kristine Peers Giacomo Borgo Jennifer Young Lauren Diamond Nathalie Moll Kevin Outterson Marc Gitzinger Deepali Patel Tim Wilsdon #antibiotics #research #stewardship #AMR #WAAW

👉 Entrevistamos a Katarina Nedog, directora asociada de regulación, desarrollo y fabricación de medicamentos en la EFPIA - European Federation of Pharmaceutical Industries and Associations, para hablar sobre cómo la reducción de ensayos clínicos en Europa impacta a las compañías farmacéuticas. 📉 En concreto, un informe de IQVIA subraya que aunque haya aumentado el 38% los ensayos clínicos globales en la última década, el número de ensayos en el Espacio Económico Europeo (EEE) ha disminuido drásticamente, reduciendo el acceso de 60.000 pacientes europeos a ensayos clínicos. #ensayosclínicos #empresas #industriasfarmacéuticas #Internacional

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐁𝐚𝐫𝐫𝐢𝐞𝐫𝐬 𝐢𝐧 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 𝐓𝐡𝐞 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐌𝐨𝐨𝐧𝐬𝐡𝐨𝐭'𝐬 𝐓𝐰𝐨-𝐘𝐞𝐚𝐫 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 Many rare diseases remain understudied, with limited research foundations. Two years ago, the Rare Disease Moonshot was launched to address these challenges through groundbreaking public-private collaboration to shift from siloed approaches to more collaborative, interconnected research methods to tackle these knowledge gaps. To mark its second anniversary, representatives from EURORDIS-Rare Diseases Europe, European Rare Disease Research Alliance (ERDERA), EFPIA - European Federation of Pharmaceutical Industries and Associations, and MEP Vlad Voiculescu took part in a Euronews debate to explore the progress made, the challenges ahead, and the systemic changes required to create lasting impact. 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐢𝐧𝐠 𝐢𝐬 𝐨𝐟𝐭𝐞𝐧 𝐭𝐡𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧  Public-private collaborations are accelerating progress by enabling knowledge sharing and aligning goals. Initiatives like IHI and IMI have demonstrated the effectiveness of partnering in delivering excellent science and speeding up R&D processes. 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐑𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐍𝐞𝐭𝐰𝐨𝐫𝐤𝐬 𝐚𝐫𝐞 𝐫𝐞𝐚𝐝𝐲 𝐟𝐨𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 ERNs have made significant contributions to data sharing and joint research. With additional support, they can maximize their research potential and integrate into the broader research ecosystem. The political momentum is now with ongoing legislative reviews and upcoming strategies, we have a unique opportunity to integrate rare disease research into future funding programmes. This momentum can drive innovation and improve the lives of millions of patients worldwide. A 𝐜𝐚𝐥𝐥 𝐭𝐨 𝐚𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐨𝐦𝐞𝐧𝐭𝐮𝐦, we need: 🤝 Continued commitment to collaborative research and public-private partnerships 🤝 Simplified funding rules to facilitate collaboration 🤝 Removal of barriers to industry partnerships 🤝 Support for European Reference Networks in research activities 🤝 Aligned and accelerated clinical trial processes across Europe 🤝 A stable environment to attract investors, retain talent, and foster innovation Let's seize this opportunity to lead in rare disease innovation. Together, we can create a unified, collaborative, and well-supported research ecosystem that brings hope to millions affected by rare diseases. More 👉 https://lnkd.in/dxUp33GN EUCOPE - European Confederation of Pharmaceutical Entrepreneurs EuropaBio - the European Association for Bioindustries Critical Path Institute (C-Path) BBMRI-ERIC ECRIN (European Clinical Research Infrastructure Network) EATRIS Together for Rare Diseases International Rare Diseases Research Consortium (IRDiRC)

Investment in medicines research and development in Europe has grown 4.4% every year between 2010 and 2022. China has grown nearly 5 times faster. How can Europe #RebootLifeSciences and close the gap? Read more: https://lnkd.in/dTQr2_iB   #WeWontRest

Health prevention tools such as screening programmes and immunisation can help protect people’s lives, generate return on investment for the economy and address the health challenges of today and tomorrow. We urgently need a paradigm shift towards prevention-based healthcare #PreventionForChange https://bit.ly/3YNvdLq